EV 048Alternative Names: rEV 048
Latest Information Update: 04 Jan 2007
At a glance
- Originator Evolutec
- Mechanism of Action Ion channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Shock
Most Recent Events
- 15 Jan 2002 rEV 048 is available for licensing (http://www.evolutec.co.uk)
- 15 Jan 2002 Preclinical development for Shock in United Kingdom (Unknown route)